NEURO61

Session information

Print

Symposium

[S-36] Symposium 36
Development of new frontier for elucidation of multiple system atrophy

Tue. Sep 1, 2020 1:45 PM - 3:15 PM Room 12 (Okayama International Center 8F event Hall)

Chair：YasuyukiOhta（Division of Neurology, Department of Internal Medicine III, Yamagata University）,KoichiWakabayashi（Department of Neuropathology, Hirosaki University Graduate School of Medicine）

[S-36-1] Cellular pathology in multiple system atrophy

○Koichi Wakabayashi (Department of Neuropathology, Hirosaki University Graduate School of Medicine, Japan)

Multisystem atrophy (MSA) is a multi-system neurodegenerative disease of the cerebellum, pyramidal and extrapyramidal tract, and autonomic nervous system, which is characterized by the α-synuclein deposition in oligodendrocytes. There are still many unsolved issues about the pathological mechanism, and there is an urgent need to develop new therapeutic agents. Researches on MSA mainly cover the pathogenesis of α-synuclein, and includes disease-causing factors in DNA polymorphisms and microRNAs, and the dysfunction of neural networks by fMRI. It is important to confirm and discuss about the latest knowledge to develop further researches on MSA. Therefore, in this symposium, the latest research results on MSA in Japan will be presented, aiming discussion between speakers and participants to establish a new research goal on MSA.

[S-36-2] Alterations of Cerebello-Cerebral Resting State Networks in Multiple System Atrophy

○Hirohisa Watanabe (Department of Neurology, Fujita Health University, Japan)

Multisystem atrophy (MSA) is a multi-system neurodegenerative disease of the cerebellum, pyramidal and extrapyramidal tract, and autonomic nervous system, which is characterized by the α-synuclein deposition in oligodendrocytes. There are still many unsolved issues about the pathological mechanism, and there is an urgent need to develop new therapeutic agents. Researches on MSA mainly cover the pathogenesis of α-synuclein, and includes disease-causing factors in DNA polymorphisms and microRNAs, and the dysfunction of neural networks by fMRI. It is important to confirm and discuss about the latest knowledge to develop further researches on MSA. Therefore, in this symposium, the latest research results on MSA in Japan will be presented, aiming discussion between speakers and participants to establish a new research goal on MSA.

[S-36-3] How does exogenous alpha-synuclein get access to the endogenous alpha-synuclein proteins?

○Takafumi Hasegawa (Division of Neurology, Department of Neuroscience & Sensory Organs, Tohoku University Graduate School of Medicine, Japan)

Multisystem atrophy (MSA) is a multi-system neurodegenerative disease of the cerebellum, pyramidal and extrapyramidal tract, and autonomic nervous system, which is characterized by the α-synuclein deposition in oligodendrocytes. There are still many unsolved issues about the pathological mechanism, and there is an urgent need to develop new therapeutic agents. Researches on MSA mainly cover the pathogenesis of α-synuclein, and includes disease-causing factors in DNA polymorphisms and microRNAs, and the dysfunction of neural networks by fMRI. It is important to confirm and discuss about the latest knowledge to develop further researches on MSA. Therefore, in this symposium, the latest research results on MSA in Japan will be presented, aiming discussion between speakers and participants to establish a new research goal on MSA.